Root Admin Guide Posted May 25, 2016 Root Admin Report Share Posted May 25, 2016 Allergan announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for oxymetazoline HCl cream 1% (Rhofade) for the treatment of persistent facial erythema associated with rosacea in adults. MPR Should be released sometime in 2017. The name Rhofade is mentioned in this article. Allergan Plc (AGN) Brenton L. Saunders on Q2 2016 Results – Earnings Call Transcript A document prepared for Allergan’s November 4, 2015 R&D Day presentation is available to download which is primarily about this new Oxymetazoline 1% Cream which may be released next year. David Pascoe has some insightful comments about this document worth reading. FDA has approved Rhofade. Link to comment Share on other sites More sharing options...
Root Admin Guide Posted June 22, 2016 Author Root Admin Report Share Posted June 22, 2016 A document prepared for Allergan’s November 4, 2015 R&D Day presentation is available to download which is primarily about this new Oxymetazoline 1% Cream which may be released next year. David Pascoe has some insightful comments about this document worth reading. Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now